Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544694 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
A Phase 3 study of Dry Eye Disease, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 79
- Enrollment target
- 4
- Study locations
NCT06544694 is a Phase 3 study of Dry Eye Disease that has completed, run by Alcon Research. The registered enrollment target is 79 participants, below the 253-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT06544694, a Phase 3 study of Dry Eye Disease, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 79 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
Conditions Studied
Interventions
- DRUG 0.003% AR-15512
- OTHER Artificial Tears
Study Locations (4)
North Carolina
- Oculus Research - Garner
- Wilmington Eye - Leland
- CORE, Inc. - Shelby
Kentucky
- Butchertown Clinical Trials - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06544694
The ClinicalTrials.gov registry entry for NCT06544694 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 253-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (69% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which 0.003% AR-15512 is the first listed.
NCT06544694 reports 4 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06544694 about?
NCT06544694 is a clinical study titled "A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease". The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
What is the current status of trial NCT06544694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 79 participants. The study started on 2024-10-08. Estimated completion is 2025-03-21.
What conditions does trial NCT06544694 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT06544694?
The interventions under investigation include: 0.003% AR-15512 (DRUG), Artificial Tears (OTHER).
Who is sponsoring clinical trial NCT06544694?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544694 being conducted?
This trial has 4 study locations across Kentucky, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
ACTIVE NOT RECRUITING · Phase 3
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
COMPLETED · Phase 3
-
A Study Designed to Evaluate Tear Production
COMPLETED · Phase 3
-
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
COMPLETED · Phase 3
-
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.